Praluent vs Repatha: Comparing PCSK9 Inhibitors
What Are PCSK9 Inhibitors?
Praluent (alirocumab) and Repatha (evolocumab) block a protein called PCSK9, which normally breaks down LDL receptors on liver cells. With more receptors intact, the liver clears more LDL cholesterol from the bloodstream. Both drugs are given as subcutaneous injections and prescribed to patients whose LDL stays too high on statins alone. The FDA approved both in 2015 for familial hypercholesterolemia and established cardiovascular disease.
How Much Each Drug Lowers LDL
Network meta-analyses consistently rank both drugs among the most effective LDL-lowering therapies available. Evolocumab tends to edge out alirocumab slightly in average LDL reduction. A 2017 analysis of 69 trials found evolocumab 140mg reduced LDL by 74% versus placebo, compared to about 60% for alirocumab 150mg. In post-commercialization studies comparing patients on effective doses, the real-world difference was small and often clinically negligible.
Cardiovascular Benefits Beyond Cholesterol
Both drugs reduce major cardiovascular events. A meta-analysis of 39 trials and 66,478 patients found PCSK9 inhibitors cut myocardial infarction risk by 20% and stroke risk by 22%. A 2025 network meta-analysis of 64,921 patients confirmed no significant difference between the two drugs for composite cardiovascular events, MI, stroke, or coronary revascularization. Neither has demonstrated a statistically significant reduction in cardiovascular death in pooled analyses.
The All-Cause Mortality Signal
Multiple meta-analyses have flagged a potential mortality advantage for alirocumab. A 2020 study of 30 trials and 59,026 patients found alirocumab associated with lower all-cause death versus evolocumab (RR 0.80, 95% CI 0.66-0.97). A 2022 Bayesian analysis reached a similar conclusion. However, these are indirect comparisons across different trial populations, not head-to-head data. The difference may reflect who was studied rather than which molecule works better.
Injection Frequency and Dosing Options
Repatha offers two regimens: 140mg every two weeks or 420mg once monthly. Both produce similar LDL reductions with comparable safety profiles. Praluent is dosed at 75mg or 150mg every two weeks, with uptitration to 150mg when targets aren't met. A 300mg monthly option exists but sees less clinical use. The monthly option with Repatha is a practical advantage for patients who prefer fewer injections.
Side Effects and Tolerability
Safety profiles are nearly identical. A 2023 meta-analysis confirmed neither drug increases risk of diabetes, neurocognitive events, liver enzyme elevation, or rhabdomyolysis compared to controls. The one reproducible difference is injection-site reactions: alirocumab carries a 27% higher risk compared to evolocumab. Serious adverse event rates and discontinuation rates are comparable. Both drugs are generally well tolerated over follow-up periods exceeding two years.
Where the Subtle Differences Lie
Indirect comparisons suggest alirocumab may have a slight edge for stroke prevention and hospitalizations for unstable angina, while evolocumab may rank marginally higher for MI reduction. A 2026 meta-analysis of 62,119 patients found alirocumab significantly reduced unstable angina hospitalizations by 42%. But these are subgroup signals from indirect analyses. No head-to-head trial has tested whether these patterns hold in a controlled comparison.
How to Decide Between Praluent and Repatha
Clinical guidelines treat these drugs as largely interchangeable. The deciding factors are practical: insurance formulary placement, copay assistance programs, preferred injection schedule, and comfort with the auto-injector device. If you prefer monthly dosing, Repatha offers that option. Your physician can evaluate your LDL targets, existing therapy, and cardiovascular risk profile to determine which drug fits best.